This article was originally published in The Tan Sheet
Reports revenues of $11.9 mil. for the third quarter ended Dec. 31, with $7.5 mil. in licensing and development fees from its agreement with American Home Products. The company reported no revenue for the comparable quarter of 1997. PharmaPrint began licensing its herbal standardization technology for single entity herbals exclusively to AHP in 1997 for use in the company's Centrum Herbals line. The products were launched in November, with ads following in January ("The Tan Sheet" Jan. 11, p. 15). PharmaPrint records net income for the quarter of $2.7 mil., compared to a net loss of $4.3 mil. in last year's third quarter. The Irvine, Calif.-based firm plans to form a partnership for the launch of combination herb/vitamin products, possibly with AHP. An alliance for the development of a pharmaceutical product "also looks promising in the near-term," the firm says. PharmaPrint is conducting a Phase II clinical trial on a saw palmetto-derived drug for benign prostatic hypertrophy
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC